Postmenopausal breast cancer: incidence-based cost of illness

References

• Nationaal Kankerregister. Kanker Algemeen. 1995: 1–4.
   Google Scholar
• Nationaal Kankerregister. Borstkanker. 1995: 1–4.
   Google Scholar
• Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Medical Decision Making 1993; 13: 322–338
   PubMed Web of Science ®Google Scholar
• Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics 1998; 13: 397–409.
   PubMed Web of Science ®Google Scholar
• Launois R, Reboul-Marty J, Henry B, Bonneterre J. A cost-utility analysis of second-line chemotherapy in metastatic breast cancer. Docetaxel versus Paclitaxel versus Vinorelbine. Pharmacoeconomics 1996; 10: 504–521.
   PubMed Web of Science ®Google Scholar
• Hansen N, Morrow M. Breast disease. Medical Clinics of North America 1998; 82; 203–222.
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998; 351: 1451–1467.
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998; 352: 930–942.
   PubMed Web of Science ®Google Scholar
• Dalberg K, Johansson H, Johansson U, Rutqvist LE, for the Stockholm Breast Cancer Study Group. A randomised trial of long term adjuvant tamoxifen plus postoperative radiation therapy versus radiation therapy alone for patients with early stage breast carcinoma treated with breast-conserving surgery. Cancer 1998; 82: 2204–2211.
   PubMed Web of Science ®Google Scholar
• Fisher B, Anderson S, Redmond CK, Wolmark N, Wickerham DL, Cronin WM. Reanalysis and results after 12 years of follow-up in a randomised clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. New England Journal of Medicine 1995; 333: 1456–1461.
   PubMed Web of Science ®Google Scholar
• Fisher B, Digman J, Mamounas EP et al. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor- negative tumors: eight-year results from national surgical adjuvant breast and bowel project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil. Journal of Clinical Oncology 1996; 14: 1982–1992.
   Google Scholar
• Wils JA, Bliss JM, Marty M et al. Epirubicin plus tamoxifen versus tamoxifen alone in node positive postmenopausal patients with breast cancer: a randomised trial of the international collaborative cancer group. Journal of Clinical Oncology 1999; 17: 1988–1998.
   PubMed Web of Science ®Google Scholar
• Cowen D, Jacquemier J, Houvenaeghel G et al. Local and distant recurrence after conservative management of “very low risk” breast cancer are dependent events: a 10-year follow-up. International Journal of Radiation Oncology and Biological Physiology 1998; 41: 801–807.
   PubMed Web of Science ®Google Scholar
• Veronesi U, Maisonneuve P, Costa A et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Lancet 1998; 352: 93–97.
   PubMed Web of Science ®Google Scholar
• Jatoi I, Hilsenbeck SG, Clark GM, Osborne CK. Significance of axillary lymph node metastasis in primary breast cancer. Journal of Clinical Oncology 1999; 17: 2334–2340.
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 1992; 339: 71–85.
   PubMed Web of Science ®Google Scholar
• Nationaal instituut voor statistiek
   Google Scholar
• Ackland SP, Anton A, Breitbach GP et al. Dose intensive epirubicin-based chemotherapy is superior to an intensive cyclophosphamide, methotrexate and fluouracil regimen in metastatic breast cancer: a randomised multinational study. Journal of Clinical Oncology 2001; 19: 943-953.
   PubMed Web of Science ®Google Scholar
• Pacini P, Rinaldini M, Algeri R et al. FEC (5-fluouracil, epidoxorubicin and cyclophosphamide) versus EM (epidoxorubicin and mitomycin-C) with or without lonidamine as first line treatment for advanced breast cancer. A multicenter randomised study. Final results. European Journal of Cancer 2000; 36: 966–975.
   PubMed Web of Science ®Google Scholar
• Rose C, Kamby C, Mouidsen HT et al. Combined endocrine treatment of elderly postmenopausal patients with metastatic breast cancer. A randomised trial of tamoxifen vs tamoxifen + aminoglutethimide and hydrocortisone and tamoxifen fluoxymesterone in women above 65 years of age. Breast Cancer Restorative Treatment 2000; 61: 103-110.
   PubMed Web of Science ®Google Scholar
• Jassem J, Pienkowski T, Pluzanska A et al. Central and Eastern Europe and Israel paclitaxel breast cancer study group. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomised phase III multicenter trial. Journal of Clinical Oncology 2001; 19: 1707–1715.
   PubMed Web of Science ®Google Scholar
• Berrino F, Sant M, Verdecchia A, Capocaccia R, Hakulinen T, Estève J. Survival of Cancer Patients in Breast Cancer, The Eurocare Study 1995. World Health Organisation, International Agency for Research on Cancer (IARC), European Commision, IARC scientific publication no 132.
   Google Scholar
• Forbes JF. The incidence of breast cancer: The global burden, public health considerations. Seminars in Oncology 1997; 24 (Suppl. 1): S1-20-S1-35.
   Google Scholar
• Koopmanschap MA, Rutten FFH. A practical guide for calculating indirect costs of disease. Pharmacoeconomics 1996; 10: 460–466.
   PubMed Web of Science ®Google Scholar
• Rice DP. Cost of illness studies: fact or fiction? Lancet 1994; 344: 1519–1520.
   PubMed Web of Science ®Google Scholar
• Mauskopf J. Prevalence based economic evaluation. Value in Health 1998; 1: 251-259.
   PubMedGoogle Scholar
• Bercez C, Lebrun T, Bonneterre ME, Sleke B, Lenne X, Bonneterre J. Advanced breast cancer: an evaluation of the cost of recurrence. Cancer 1999; 86: 585–590.
   Web of Science ®Google Scholar
• Wolstenholme JL, Smith SJ, Whynes DK. The costs of treating breast cancer in the United Kingdom: implications for screening. International Journal of Technology Assessment in Health Care 1998; 14: 277–289.
   PubMed Web of Science ®Google Scholar
• Legoretta AP, Brooks RJ, Leibowitz AN, Solin LJ. Cost of breast cancer treatment. A 4-year longitudinal study. Archives in Internal Medicine 1996; 156: 2197–2201.
   PubMedGoogle Scholar
• Mitlak BH, Cohen FJ. Selective estrogen receptor modulators: a look ahead. Drugs 1999; 57: 653–663.
   PubMed Web of Science ®Google Scholar